Regenerative medicine approaches for sensory

Caeregen Therapeutics is focused on developing innovative therapies aimed at repairing and restoring damaged tissues, particularly in the context of sensory-related diseases. Their primary therapeutic candidate, Noregen® (CTR-107), is a synthetic protein designed to mimic the naturally occurring protein norrin, which plays a crucial role in retinal vascular development. This novel approach targets the progressive loss of capillary vessels in the retina, promoting their organized regrowth and potentially restoring vision in conditions such as Familial Exudative Vitreoretinopathy (FEVR). The company is also exploring the application of Noregen in other retinal diseases, including diabetic retinopathy and age-related macular degeneration, highlighting its versatility in addressing various forms of vision loss.

The scientific foundation of Caeregen's work lies in regenerative medicine, which encompasses a range of strategies to repair or replace damaged cells and tissues. Their research emphasizes the importance of restoring normal cellular signaling and microenvironments to facilitate healing. By leveraging the biological pathways associated with cellular and organ development, Caeregen aims to develop targeted therapies that not only halt disease progression but also promote the regeneration of essential structures within the eye and potentially other sensory systems. This commitment to advancing regenerative therapies positions Caeregen Therapeutics at the forefront of addressing unmet medical needs in the field of vision restoration.

United States

Caeregen Therapeutics discovers and develops novel therapies which repair, restore, and protect damaged and diseased tissues by reactivating the pathways and signaling which accompany normal cellular and tissue development. Our revolutionary regenerative medicine approaches have the potential to restore lost or degraded functioning to diseased tissue and organs.

Caeregen Therapeutics

Company Details